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Muscle mass loss or sarcopenia is a principle component of malnutrition which prevails in 65-90% 
of patients with end-stage liver disease [1]. Intuitively, the roots of malnutrition play a precipitating 
role in muscle catabolism. Undernutrition frequently occurs in cirrhosis since an inadequate diet is 
compounded by a hypermetabolic energy demand. However, multiple other factors contribute to the 
pathogenesis of malnutrition including malabsorption of nutrients, metabolic alterations, increased 
intestinal protein losses, reduced protein synthesis, increased protein catabolism and disturbance of 
substrate utilization [2,3]. Sarcopenia adversely affects quality of life, leads to longer hospitalizations, 
increases susceptibility to infections, negatively impacts clinical outcomes pre- and post-liver 
transplantation and is an independent prognostic factor for survival in patients with cirrhosis [4]. The 
pathophysiological pathways triggering a reduction in muscle protein synthesis and/or an increase in 
proteolysis, resulting in loss of muscle mass, remain elusive. Furthermore, in addition to loss of 
quantity, quality of muscle is also affected during muscle wasting. Altered muscle metabolism and 
contractile function, concomitant with a reduction in muscle mass, contributes to the onset of frailty as 
well as functional decline in physical performance, leading to increased morbidity in patients with 
cirrhosis [5]. 
The liver is a powerful metabolic organ which in addition to being the center for the metabolism of 
nutrients (glucose and lipids), also plays a major role in ammonia disposal. Exclusively expressing all 
the enzymes of the urea cycle, the liver regulates the circulating blood ammonia levels arising from the 
gut (primary source of ammonia generation). Thus, severe liver impairment, leads to the occurrence of 
hyperammonemia. At physiological pH, the majority (98%) of ammonia is found in ionic form (NH4
+
) 
with ~ 2% arising in gas form (NH3). Both forms are capable of crossing cellular membranes. NH3 via 
diffusion and NH4
+ 
via K
+
-channels and cotransporters since NH4
+
 has very similar ionic properties 
(ionic radius and diffusion coefficient) to K
+
. In addition, specific ammonia transporters have also been 
identified [6]. Subsequently, following its concentration gradient, ammonia is dispersed throughout the 
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body, entering all cells, organs and tissues. Elevated concentrations of ammonia (including increased 
flux (uptake) of ammonia across cell membranes) lead to changes in pH, adjusted membrane potential 
and altered cell metabolism, which independently and/or collectively lead to a cascade of 
pathophysiological events [7]. Since ammonia easily crosses the blood-brain barrier, blood-derived 
ammonia leads to neurotoxic levels of ammonia in the brain which is a fundamental component 
implicated in the pathogenesis of hepatic encephalopathy (HE).  
Aside from primarily affecting the brain, the toxicity of ammonia has also demonstrated to affect 
other organs and tissues, including muscle. Muscle plays a significant compensatory role in detoxifying 
ammonia during liver disease since it houses the enzyme glutamine synthetase (GS), an important 
ammonia removing pathway during the amidation of glutamate to glutamine. Therefore, in the setting 
of liver disease, reduced capacity to remove ammonia in the liver, aggregated with muscle mass 
depletion, further reduces the body’s capacity to clear ammonia which in turn leads to a higher risk of 
developing hyperammonemia and HE [8]. However, paradoxically, within the last 5 years, Dasarathy 
and colleagues have provided solid evidence that elevated levels of ammonia cause detrimental effects 
to the muscle. It has been shown that elevated ammonia i) upregulates myostatin (an autocrine growth 
inhibitor) in myotubes through a NF-κB-dependent pathway [9], ii) stimulates muscle autophagy [10] 
and iii) impairs skeletal muscle contractility and strength [11]. In the recent issue (JHEPAT-D-15-
02306R2), Davuluri and colleagues, using human tissue as well as in vitro and in vivo models of 
hyperammonemia (including knockout and knockdown of a number of molecular targets), elegantly 
identified the molecular pathways implicated in the inhibition of muscle protein synthesis in patients 
with cirrhosis and hyperammonemia [12]. The authors found that ammonia activated the general 
control nonderepressible 2 (GCN2) kinase (amino acid deficiency sensor) which inactivated the 
eukaryotic initiation factor 2 (eIF2α) (via phosphorylation of the α subunit) and additionally inactivated 
mTORC1, resulting in global repression of mRNA translation and hence protein synthesis in the 
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skeletal muscle. Under physiological conditions, phosphorylation of eIF2α is followed by an adaptive 
integrated stress response (ISR) that is mediated via upregulation of activating transcription factor 4 
(ATF4) which through downstream signalling pathways leads to the reversible dephosphorylation of 
phospho-eIF2α. Here, authors demonstrated that loss of feedback negative loop of ISR during 
hyperammonemia, as evidenced by failure in ATF4 induction, results in chronic and persistent low 
protein synthesis. Since the effects of increased ammonia (pH, membrane potential and metabolism) 
touch all cells within the body and therefore, are not specific to the brain, the importance of 
hyperammonemia and its impact on clinical outcomes merits to be thoroughly investigated.  
Davuluri and colleagues also demonstrated in this issue (JHEPAT-D-15-02306R2) the 
therapeutic benefit of L-leucine on muscle protein synthesis that was due to the metabolic adaptation of 
muscle to hyperammonemia. Leucine, a branched-chain amino acid (BCAA), is capable of activating 
mTORC1 and activating protein synthesis [13]. Furthermore, the authors demonstrated that L-leucine 
reversed GCN2-eIF2α phosphorylation, removing protein synthesis inhibition. The authors determined 
that leucine “starvation”, provoked by ammonia, resulted in a compensatory upregulation of the leucine 
transporter (leucine/glutamine exchanger (SLC7A5)) and therefore leucine supplementation rescued 
the inhibition of protein synthesis.  
Davaluri and colleagues administered 15g of leucine-enriched BCAA (7.5g L-leucine, 3.75g L-
isoleucine and 3.75g L-valine) to 6 hyperammonemic patients with cirrhosis and demonstrated a 
reversal in muscle protein synthesis inhibition. However, muscle mass (quantity or quality) was not 
evaluated, most likely due to short treatment time of 7 hours. A supporting study by Les et al., 2011 
demonstrated leucine-enriched BCAAs (13.5g L-leucine, 9g L-isoleucine and 7.5g L-valine) given as a 
nutritional supplementation for 56 weeks lead to an improvement in muscle mass (mid-arm muscle 
circumference) in 46 patients with cirrhosis [14]. To date, only one study has tested the independent 
effect of L-leucine and, following 10g/day supplementation for 12 weeks to 9 patients with cirrhosis, 
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thigh circumference was not enhanced [15]. This study puts in question the beneficial effect of L-
leucine on optimizing muscle mass. However, following the positive results of Davuluri and 
colleagues, a time-dependent, dose-response study evaluating the effect of L-leucine on muscle mass 
merits to be thoroughly conducted. 
The beneficial effect of L-leucine on muscle protein synthesis and subsequently muscle wasting 
may also be a result of lowering ammonia. BCAAs are highly metabolized in the muscle and are 
capable of replenishing α-ketoglutarate, believed to be depleted during hyperammonemia as α-
ketoglutarate is aminated to glutamate which subsequently is amidated to glutamine. These ammonia-
removing pathways are stimulated during hyperammonemia in attempt to reduce ammonia. BCAAs 
have been reported to lower blood ammonia following 3 months of daily supplementation (0.24g/kg; 
50% L-leucine, 25% isoleucine and 25% valine) in patients with cirrhosis which was associated with an 
improvement in HE [16]. The treatment time and dose appear to be vital as 3-hour administration of 
BCAAs (0.45g/kg; 45.5% L-leucine, 30% isoleucine and 24.5% valine) did not lower blood ammonia 
in patients with cirrhosis but did increase BCAA-derived ammonia clearance in muscle [17]. It remains 
to be defined whether the beneficial effect of L-leucine (BCAA) on muscle protein synthesis is due to a 
lowering of blood ammonia. 
Patients with cirrhosis and sarcopenia have a higher risk of developing HE [8] as loss of muscle 
mass, in addition to liver impairment, further reduces the capacity of ammonia removal, leading to 
higher risk of hyperammonemia [18]. There is an invested interest in improving extra-hepatic ammonia 
clearance (targeting GS in the muscle) for the treatment of HE [19]. Both L-ornithine L-aspartate and 
L-ornithine phenylacetate have demonstrated to lower blood ammonia by generating glutamate and 
stimulating GS activity in the muscle [20,21]. However, L-ornithine phenylacetate may be more 
efficient by chelating glutamine released during muscle catabolism and preventing ammonia generation 
through glutaminase activity. Overall, increasing the muscle’s capacity to clear ammonia by either 
stimulating GS activity and/or optimizing muscle mass are attractive strategies for the treatment and 
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prevention of HE. A recent meta-analysis revealed that BCAAs have a beneficial effect on HE [22]; 
however the precise mechanisms remain unclear. Interestingly, exercise has been shown to be 
advantageous in optimizing muscle mass in patients with liver disease [23] and furthermore, in 
combination with L-leucine supplementation, exercise demonstrated to a have greater impact of muscle 
mass which was associated with an improvement in minimal HE compared to L-leucine alone [15]. The 
independent effect of exercise on HE has not been evaluated.   
In conclusion, the integrated relationship between muscle (mass and activity of GS), ammonia 
and cognitive function remains to be comprehensively investigated. Studies evaluating the beneficial 
effect of improving muscle mass on ammonia clearance and the treatment and prevention of HE are 
lacking. The data presented by Davuluri and colleagues highlights the important contribution of 
hyperammonemia on the inhibition of muscle protein synthesis and muscle mass wasting in cirrhosis. 
This depicts the toxicity of ammonia lies beyond the brain and provides compelling evidence that long-
term treatment of hyperammonemia can be beneficial for the muscle and the brain in cirrhosis, 
improving clinical outcomes pre- and post-liver transplantation.  
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